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NKG2D and DNAM-1 are two activating receptors, present on the surface of NK cells
and other cells of the immune system. Their ligands – MICA, MICB, ULBP1-6 for NKG2D,
PVR/CD155 and Nectin-2/CD112 for DNAM-1 – can be constitutively expressed at low levels
in some normal cells, but they are more often defined as “stress-induced,” since different
stimuli can positively regulate their expression. In this review, we describe the molecular
mechanisms involved in the up-regulation of NKG2D and DNAM-1 ligands under different
physiological and pathological “stress” conditions, including mitosis, viral infections, and
cancer. We will focus on the DNA damage response, as recent advances in the field have
uncovered its important role as a common signaling pathway in the regulation of both
NKG2D and DNAM-1 ligand expression in response to very diverse conditions and stimuli.
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INTRODUCTION
The immune system is tasked with protecting the organism from
pathogen attack, but also with patrolling cells and tissues that have
been dysregulated by non-microbial challenges, such as ultraviolet
radiation, heat shock, oxidative stress, or tumor transformation.
From a certain point of view, all these responses are not com-
pletely unrelated. In fact, one prominent consequence common
to different types of stressors is the up-regulation of the MHC
class I-like proteins MICA, MICB, ULBP1-6, which are present
at low to undetectable levels in normal cells, but can be induced
both by infectious agents and by sterile stresses, including cell divi-
sion and/or tumor transformation (1–4). These molecules are the
ligands of the activating receptor NKG2D, a member of the C-
type lectin-like superfamily of innate receptors, able – alone or in
combination with other receptors – to activate the effector func-
tions of NK cells, CD8+ T cells, γδ T cells, and a subset of CD4+ T
cells (1). Though less characterized, DNAM-1 is another activating
receptor expressed by cytotoxic lymphocytes, and its ligands PVR
and Nectin-2, two adhesion molecules belonging to the Ig-like
superfamily, are similarly induced by cellular stresses (5–9). Thus,
expression of ligands for activating NK cell receptors appears to be
a critical mechanism of immunosurveillance against stressed cells
(10). In addition, recent studies demonstrated that another shared
aspect of stress responses consists in the activation of the DNA
damage response (DDR), a major signaling pathway implicated in
the up-regulation of ligand expression (11).
DNA must be protected from damage produced spontaneously
during DNA replication or from endogenously generated reactive
oxygen species (ROS) that are a byproduct of normal meta-
bolic processes. In addition, a plethora of external stimuli, such
as ultraviolet light, ionizing radiation, and viral infections can
cause DNA lesions (both in a ROS-dependent and -independent
manner) that can block genome replication and transcription
(12). Therefore, the general term DDR is related to a complex
series of cellular stress-induced pathways that detect DNA dam-
age and that are involved in the maintenance of genome integrity
and avoidance of mutated DNA duplication (13). Three mem-
bers of the phosphatidylinositol 3-kinase-like serine/threonine
protein family are central to this response: ATM, ATR, and the
DNA-dependent protein kinase (DNA-PK) (14, 15). Both ATM
and DNA-PK are known to be recruited to and activated by
double-stranded DNA breaks, while ATR is activated by stalled
replication forks and subsequently single-stranded DNA breaks
(16–18). Following the recognition of DNA lesions by sensor pro-
teins, these kinases activate many downstream mediators, such as
the serine/threonine kinases Chk1 and Chk2, able to phosphory-
late many effector proteins that induce either cell-cycle arrest and
DNA repair or, if unsuccessful, initiation of programs instruct-
ing the cell to undergo apoptosis or enter terminal differentiation
through senescence (12–14).
NORMAL CELLS
There is a substantial body of evidence showing the involve-
ment of DDR in many physiological processes, such as mitosis
(19), insulin response (20), V(D)J recombination (21, 22), or after
lipopolysaccharide stimulation in macrophages (23). In addition,
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the self-renewal capacity of hematopoietic stem cells was found
to depend on an ATM-mediated modulation of the response to
oxidative stress (24). Enhanced phosphorylation of either ATM or
one of its substrates, the histone H2AX, as well as the increase of
ATM protein levels were observed on T cells upon activation in
response to a plethora of stimuli (8, 25–27).
In relation to activating ligands, studies performed in our own
and other laboratories have shown that MIC, ULBP, and PVR
molecules are induced on antigen-activated T cells (8, 27–29)
(Table 1). Interestingly, both oxidative stress (mainly mediated
by a macrophage-dependent production of ROS) and DDR were
implicated in the induction of MICA and PVR on activated T cells
(8, 27), suggesting that signaling via ATM/ATR kinases and DDR
could represent a common pathway regulating the expression of
NKG2D and DNAM-1 ligands on T lymphocytes (Figure 1). Of
note, PVR and NKG2D ligand expression on T cells was mainly
associated with progression to the S and G2/M phases of the
cell (8) (and our unpublished observations). Since ATM/ATR
are known to be regulators of cell division, the increased cellu-
lar proliferation upon antigenic stimulation could be the crucial
signal resulting in NKG2D and DNAM-1 ligand expression on
healthy cells. In fact, a correlation of either NKG2D ligand or PVR
expression with cell proliferation has been documented in several
studies. Expression of MICA has been shown in fast dividing tis-
sues including the gut epithelium (30) and in highly proliferating
cell lines (31). Indeed, high surface MICA expression was detected
in fibroblasts during the stage of rapid growth and was strongly
down-regulated following cell–cell contact (32). Similarly, PVR
expression in epithelial cells was tightly regulated by changes in cell
density (33). Groh and colleagues have also demonstrated that the
presence of MIC molecules on rheumatoid arthritis synoviocytes
was strongly associated with the expression of the nuclear Ki-67
proliferation marker (31). A recent study indicated that MICA
expression levels on endothelial cells were substantially increased
by the induction of cell proliferation mediated by FGF-2 or wound
healing (34). These in vitro observations were further supported
by in vivo studies performed in rodents. Using bromodeoxyuri-
dine incorporation in murine bone marrow grafts, RAE-1 (the
murine orthologs of ULBP proteins) was detected on a large frac-
tion of donor proliferating progenitor cells in the spleen of the
transplant recipients rather than on the long-term hematopoietic
stem cells (35), and in relation to DNAM-1 ligands, a study in
the rat showed that the presence of PVR in the liver was con-
fined to proliferating hepatocytes during liver regeneration (33).
When the transcriptional regulation of activating ligands was ana-
lyzed in normal proliferating cells, their expression was reported
to depend on NF-kB, Sp1, and the E2F family of transcription
factors (27, 36–38).
The biological significance of an increased expression of both
NKG2D and DNAM-1 ligands on the surface of dividing cells
could be to alert the immune system of a potentially dangerous
cell-cycle progression. Indeed, Davis’s group reported that human
NK cells bound to cells in mitosis more efficiently than the same
cells in other stages of the cell cycle (39) and our studies further
demonstrated that proliferating T cells become more susceptible
to NK cell-mediated recognition and killing (8) (Figure 1). Thus,
NK cell restriction of T cell responses might be relevant in the
maintenance of lymphocyte homeostasis as well as in the context
of autoimmunity or graft-versus-host disease (3).
VIRALLY-INFECTED CELLS
Infection by several viruses, including herpesviruses, adenoviruses,
papillomaviruses, and retroviruses, is sufficient to activate some or
all of the DDR-mediated repair pathways. Simplistically, this was
perceived as recognition by the host cell of the incoming genetic
material as its own damaged DNA, but it is now considered to
be, at least in part, an anti-viral response aimed at combating
the pathogen by posing a threat to viral genome integrity and
replication (40). However, viruses have evolved a complex rela-
tionship with the DDR pathway being able to either inhibit or
exploit DDR components in order to favor their own replica-
tion process, with some viruses using both strategies in a spatially
Table 1 | DDR-dependent up-regulation of NKG2D and DNAM-1 ligand expression.
Activator Cell model Activating ligand Reference
ATM, ATR T lymphocytes MICA (27)
ATM, ATR T lymphocytes PVR (8)
ATM LPS-stimulated macrophages MICA (23)
ATR HIV-1 infected T cells NKG2D ligands (46, 47)
ATR HIV-1 infected T cells PVR (50)
ATM, ATR, Chk1 Hepatoma MICA/B (69)
ATM Hepatoma MICB (68)
ATM, ATR Cervical and colon carcinoma, T cell leukemia ULBP2 (67)
ATM, Chk2 Multiple myeloma MICA (65)
ATM/ATR Multiple myeloma MICA/B, ULBP1-3 (7)
ATM/ATR Ewing sarcoma MICB (70)
ATM, Chk2 Colon cancer cells MICA/B, ULBP1-3 (71)
p53 Lung cancer ULBP1-2 (73)
p53 Colon/breast cancer ULBP2 (74)
ATM, Chk1 Murine ovarian tumor cells RAE-1 (11)
ATM Murine B cell leukemia PVR (66)
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FIGURE 1 | Schematic representation of the variety of stimuli that can
up-regulate NKG2D and DNAM-1 ligands. There is evidence that both in
normal cells (e.g., antigen-activated T lymphocytes), as well as in
pathological conditions, including virally-infected cells (in particular with
HIV-1) and cancer cells, a major regulatory pathway involved in ligand
up-regulation is the DNA damage response (DDR), activated by different
stimuli. The increased expression of activating ligands has been shown to
be implicated in the recognition and elimination of “stressed” cells by NK
cells, and presumably also by other cytotoxic cells (i.e., γδT cells and CD8+
T cells).
and temporally orchestrated manner (41, 42). From a theoretical
point of view, the viral-induced activation of DDR and the conse-
quent up-regulation of the ligands for activating receptors could
render infected cells susceptible to the recognition and elimina-
tion by cytotoxic lymphocytes, thus contributing to the anti-viral
response. In humans, up-regulation of NKG2D and/or DNAM-1
ligands was indeed observed following infection by several viruses
(e.g., HCMV, HCV, EBV, HIV-1) (43, 44), but the link between this
phenomenon and DDR activation has been investigated only for
HIV-1. Studies performed in our own and other laboratories have
shown that HIV-1 infection of CD4+ T lymphocytes up-regulates
both MIC and ULBP proteins, especially ULBP2, as well as PVR,
and thus exposes infected cells to recognition and lysis by NK cells
(45–49) (Figure 1). Recently, the HIV-1 Vpr protein was iden-
tified as the key viral factor responsible for the up-regulation of
both NKG2D ligands and PVR in infected CD4+ T cells (46, 47, 50)
(Table 1). The stimulatory effect of Vpr on ligand expression relies
on its capacity to recruit a cullin-ring E3 ubiquitin ligase (DDB1-
CUL4A) and to activate ATR (46, 51). The same Vpr interactions
ultimately lead infected cells to arrest in G2, a phase of the cell cycle
that allows efficient virus production (52, 53), therefore it is possi-
ble that ligand up-regulation is secondary to G2 arrest. Apparently,
the effects of Vpr on ULBP2 and PVR expression operate at dif-
ferent levels, since ULBP2 but not PVR transcripts accumulate in
Vpr-expressing cells (46, 47, 50). Thus, additional work is clearly
needed to understand how Vpr up-regulates each ligand.
As a countermeasure for ligand up-regulation, HIV-1 as well
as many other viruses, have developed the capacity to inhibit cell-
surface ligand expression. For HIV-1, this activity is mediated by
the viral proteins Nef, Vif, and Vpu that down-regulate NKG2D
ligands and/or PVR, and, as a consequence, decrease the suscep-
tibility of HIV-infected cells to NK-cell-mediated lysis (45, 48,
54). Interestingly, T cells infected with a mutated virus defective
for the expression of the two proteins, Vpr and Nef, that exert
opposite effects on NKG2D ligand and PVR expression, display
higher ligand levels compared to uninfected cells (50) (and our
unpublished data), suggesting the existence of an additional Vpr-
independent mechanism of ligand up-regulation. This mechanism
may be related to the previously reported triggering of ATM during
HIV-1 DNA integration (55).
In sum, a picture is emerging in which HIV-1 hijacked some
cellular DDR effector molecules that are required for efficient
viral replication and, at the same time, has developed means to
contrast the effect of DDR activation on NKG2D and DNAM-1
ligand expression that is dangerous for the virus itself. The fact
that also several other viruses (e.g., HCMV, KSHV, HCV, HAdV,
HHV, HCV) have evolved the capacity to down-regulate NKG2D
and DNAM-1 ligands, suggests that activating NK cell receptors
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and host immune responses mediated by NKG2D and DNAM-1
represent a serious threat that a virus must circumvent. Interest-
ingly, these viruses are known to interact at some point of their
life cycle with at least one component of the DDR machinery to
aid their own replication. Therefore, a better understanding of the
dual (pro- and anti-viral) role of DDR in the life cycle of HIV-1
and of other viruses may lead to new strategies aimed at suppress-
ing viral replication while maintaining and, possibly, reinforcing
anti-viral immune responses.
CANCER CELLS
The relevance of NKG2D in tumor surveillance has been demon-
strated by in vivo experiments showing that overexpression of
NKG2D ligands in cancer cells causes tumor rejection in mice (56,
57), and that NKG2D-deficient animals are defective in tumor sur-
veillance in models of spontaneous malignancy (58). In humans,
it has been shown that many tumors up-regulate NKG2D ligands,
probably as a result of the oncogenic process itself, and this ren-
ders them more sensitive to recognition by NK and cytotoxic T
cells (59–61). In relation to DNAM-1, in vitro studies have shown
that this activating receptor triggers NK cell-mediated killing of a
range of tumor cells expressing PVR and/or Nectin-2. Moreover,
DNAM-1-deficient mice show an impaired clearance of PVR-
expressing tumor cells and develop more tumors in response to
chemical carcinogens (62).
In cancer cells, stress signals, and in particular those associated
with DDR, induce both NKG2D and DNAM-1 ligand expression
(7, 11) (Table 1). In fact, cells exposed to chemotherapeutic agents,
genotoxic stimuli, or stalled DNA replication cycles, up-regulate
NKG2D ligands through the activation of the DDR, suggesting
that ATM, ATR, and Chk1 may be predominantly responsible for
NKG2D ligand expression maintenance (11). These findings pro-
vided for the first time a link between the constitutive activation
of DDR in tumors and the frequent up-regulation of NKG2D
ligands in transformed cells, suggesting that constitutive ligand
expression could be maintained by persistent genotoxic stress in
tumor cell lines. Moreover, many evidences support the idea that
DDR can be frequently activated in early neoplastic lesions, and
probably NKG2D and DNAM-1 ligand induction by DNA dam-
age represents a tumor surveillance mechanism operating at the
very early stages of tumorigenesis, possibly increasing the sensi-
tivity of damaged cells to NK- and/or T cell-mediated lysis (11,
63–66) (Figure 1). In particular, Croxford and colleagues have
very recently provided the first in vivo evidence that T and NK
cells play a critical role in the regression of B cell lymphomas
in Eµ-myc mice, by showing that spontaneous rejection requires
the expression of PVR on tumor cells, which is regulated by an
ATM-initiated DDR (66). Studies from our laboratory have also
contributed to better delineate the link between activation of DDR
and regulation of NKG2D and DNAM-1 ligands. In particular, we
demonstrated that genotoxic drugs, when used at doses that do
not affect cell viability, induce the up-regulation of NKG2D and
DNAM-1 ligand expression on several multiple myeloma cell lines
and primary malignant plasma cells, and consequently enhance
NK cell degranulation toward drug-treated tumor cells. This effect
is dependent on the activity of ATM/ATR kinases, and occurs in
combination with the establishment of a chemotherapy-induced
senescent phenotype (7). Our observations in multiple myeloma
are consistent with a number of other studies describing NKG2D
ligand regulation by several DNA-damaging conditions (11, 65,
67–70) (Table 1). Moreover, Leung and colleagues have recently
reported the up-regulation of NKG2D ligands by the aldosterone
antagonist spironolactone through the DNA damage-independent
activation of ATM-Chk2 in multiple colorectal cancer cells. The
drug-mediated effect requires the activation of retinoid X receptor
γ (RXRγ), probably capable of initiating chromatin remodeling,
and results in activation of the ATM-Chk2 DNA repair check-
point pathway that enhances NKG2D ligand expression (71).
These observations demonstrate a key role for the protein kinases
mediating DDR activation in the promotion of NKG2D ligand
expression, and suggest that DNA lesions are not a prerequisite
necessary to these effects.
One of the most extensively studied component of DDR is
the tumor suppressor protein p53, and DNA damage leads to
enhanced stability and activity of p53 upon its ATM-mediated
phosphorylation (72). Conflicting results have been reported
about the involvement of p53 in the regulation of NKG2D lig-
ands, with data showing positive, negative, or no effect. Gasser
and colleagues ruled out p53 from the mechanisms at the basis of
genotoxic drug-induced NKG2D ligand up-regulation in mice and
human cell lines, since the lack of p53 had no effect on NKG2D
ligand expression after genotoxic stress (11). By contrast, other
studies showed that ULBP1 and ULBP2 are direct p53 target genes
in human cell lines and, accordingly, treatment of certain cancer
cells with RITA, a small molecular compound that reactivates wild-
type p53, resulted in the up-regulation of ULBP2 expression (73,
74). On the contrary, it has been recently shown that ULBP2 gene
can be repressed via the p53-mediated increase in cellular miR-34
levels (75). Thus, the outcome of p53 activation on ULBP2, and
possibly other NKG2D ligands, might depend on the context of its
activation, pointing to a complex role of p53 that awaits further
investigation.
A novel perspective in the regulation of MICA expression has
been recently demonstrated by a study showing that up-regulation
of MICA by genotoxic stress was enhanced by inhibiting STAT3
activity in both cancer and non-malignant cells (76). In agree-
ment with this observation, studies conducted by our group
have demonstrated that inhibition of STAT3 – obtained by using
GSK3 kinase activity inhibitors – can enhance the expression
of MICA induced by the chemotherapeutic drug melphalan in
multiple myeloma cells (77). Therefore, these results add an addi-
tional layer of complexity in the molecular mechanisms regulating
the expression of MICA and likely of other NK cell activating
ligands.
CONCLUSION
As shown in less of 10 years of intense research, NK cell activat-
ing receptors and their ligands represent an important warning
system alerting cytotoxic lymphocytes of danger and stress sig-
nals. Since the expression of NKG2D and DNAM-1 ligands is
rarely seen in normal cells, this means that small changes in their
cell-surface levels may significantly influence the susceptibility of
the target cell to NK cell recognition. Their expression appears
to be regulated at different levels (epigenetic, transcriptional,
Frontiers in Immunology | NK Cell Biology January 2014 | Volume 4 | Article 508 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cerboni et al. DDR regulates NKG2D/DNAM-1 ligand expression
post-transcriptional), but in this review we have summarized
the current literature and highlighted the importance of the
DDR in promoting NKG2D and DNAM-1 ligand expression,
both at protein and mRNA levels, though the precise molecular
mechanisms mediating these effects and the possible coopera-
tion/regulation with upstream and downstream additional sig-
naling pathways remain to be further clarified. However, DDR
may represent a crucial point of convergence for ligand up-
regulation, triggered by a big variety of circumstances and stressful
stimuli.
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